Literature DB >> 25176053

Il-31 does not correlate to pruritus related to early stage cutaneous T-cell lymphomas but is involved in pathogenesis of the disease.

Marta Malek1, Jolanta Gleń, Krzysztof Rębała, Anna Kowalczyk, Michal Sobjanek, Roman Nowicki, Katarzyna Ruckemann-Dziurdzińska, Małgorzata Sokołowska-Wojdyło.   

Abstract

Mycosis fungoides (MF) and Sézary syndrome (SS) belong to the group of primary cutaneous T-cell lymphomas (CTCL). Regardless of the stage of the disease, patients with MF and SS can suffer from chronic pruritus. The aim of the study was to investigate the correlation between the interleukin 31 (IL-31) serum level, the degree of pruritus and CTCL severity; and to compare the frequency of IL-31 gene polymorphisms between patients and the control group, and between patients at different stages of the disease. Pruritus affected 67.7% of patients with MF and SS in our study. The IL-31 serum level was significantly higher in CTCL patients than in the control group but there were no positive correlation between IL-31 serum level and pruritus. A statistically significant difference in allele frequencies for IL-31 IVS2+12 gene polymorphisms between early and advanced stages was detected; GAG haplotype was more frequent and AGA was less frequent in stage IA patients compared with patients in the other stages of the disease.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25176053     DOI: 10.2340/00015555-1958

Source DB:  PubMed          Journal:  Acta Derm Venereol        ISSN: 0001-5555            Impact factor:   4.437


  16 in total

Review 1.  The biomarker landscape in mycosis fungoides and Sézary syndrome.

Authors:  Brittany Dulmage; Larisa Geskin; Joan Guitart; Oleg E Akilov
Journal:  Exp Dermatol       Date:  2017-02-02       Impact factor: 3.960

Review 2.  IL-31: State of the Art for an Inflammation-Oriented Interleukin.

Authors:  Francesco Borgia; Paolo Custurone; Federica Li Pomi; Raffaele Cordiano; Clara Alessandrello; Sebastiano Gangemi
Journal:  Int J Mol Sci       Date:  2022-06-10       Impact factor: 6.208

3.  Correlation of IL-31 gene polymorphisms with susceptibility and clinical recurrence of bladder cancer.

Authors:  Qin Li; Tielong Tang; Peng Zhang; Chenlu Liu; Yan Pu; Yan Zhang; Huizi Song; Yanyun Wang; Yaping Song; Min Su; Bin Zhou; Lin Zhang
Journal:  Fam Cancer       Date:  2018-10       Impact factor: 2.375

Review 4.  Pruritus Reduction with Systemic Anti-lymphoma Treatments in Patients with Cutaneous T Cell Lymphoma: A Narrative Review.

Authors:  Halle Field; Ling Gao; Pooja Motwani; Henry K Wong
Journal:  Dermatol Ther (Heidelb)       Date:  2016-09-02

Review 5.  Dermatitis Herpetiformis: Novel Perspectives.

Authors:  Emiliano Antiga; Roberto Maglie; Lavinia Quintarelli; Alice Verdelli; Diletta Bonciani; Veronica Bonciolini; Marzia Caproni
Journal:  Front Immunol       Date:  2019-06-11       Impact factor: 7.561

Review 6.  Interleukin-31 as a Clinical Target for Pruritus Treatment.

Authors:  Kenji Kabashima; Hiroyuki Irie
Journal:  Front Med (Lausanne)       Date:  2021-02-12

Review 7.  Interleukin-31 and Pruritic Skin.

Authors:  Masutaka Furue; Mihoko Furue
Journal:  J Clin Med       Date:  2021-04-28       Impact factor: 4.241

Review 8.  IL-31, itch and hematological malignancies.

Authors:  Eleonora Di Salvo; Alessandro Allegra; Marco Casciaro; Sebastiano Gangemi
Journal:  Clin Mol Allergy       Date:  2021-06-12

9.  IL-31 is overexpressed in lichen planus but its level does not correlate with pruritus severity.

Authors:  Kalina Welz-Kubiak; Anna Kobuszewska; Adam Reich
Journal:  J Immunol Res       Date:  2015-02-03       Impact factor: 4.818

Review 10.  MicroRNAs in the Pathogenesis, Diagnosis, Prognosis and Targeted Treatment of Cutaneous T-Cell Lymphomas.

Authors:  Maria Gluud; Andreas Willerslev-Olsen; Lise Mette Rahbek Gjerdrum; Lise M Lindahl; Terkild B Buus; Mads Hald Andersen; Charlotte Menne Bonefeld; Thorbjorn Krejsgaard; Ivan V Litvinov; Lars Iversen; Jürgen C Becker; Jenny L Persson; Sergei B Koralov; Thomas Litman; Carsten Geisler; Anders Woetmann; Niels Odum
Journal:  Cancers (Basel)       Date:  2020-05-13       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.